Marshall Wace LLP Takes Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Marshall Wace LLP acquired a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 1,130,455 shares of the biotechnology company's stock, valued at approximately $8,365,000. Marshall Wace LLP owned approximately 0.37% of Iovance Biotherapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of IOVA. AlphaQuest LLC lifted its holdings in Iovance Biotherapeutics by 63.6% during the 4th quarter. AlphaQuest LLC now owns 4,613 shares of the biotechnology company's stock worth $34,000 after buying an additional 1,794 shares during the period. SBI Securities Co. Ltd. bought a new position in Iovance Biotherapeutics during the 4th quarter worth approximately $36,000. Integrity Wealth Advisors Inc. acquired a new position in shares of Iovance Biotherapeutics in the 4th quarter worth approximately $77,000. Jump Financial LLC bought a new stake in shares of Iovance Biotherapeutics in the 4th quarter valued at $79,000. Finally, Impact Partnership Wealth LLC acquired a new position in Iovance Biotherapeutics in the fourth quarter valued at $83,000. Institutional investors own 77.03% of the company's stock.

Analyst Ratings Changes

Several research firms have recently weighed in on IOVA. Chardan Capital lowered their price objective on Iovance Biotherapeutics from $34.00 to $30.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Piper Sandler lowered their target price on Iovance Biotherapeutics from $7.50 to $6.00 and set a "neutral" rating for the company in a report on Friday, February 28th. Barclays reduced their price objective on shares of Iovance Biotherapeutics from $22.00 to $5.00 and set an "overweight" rating for the company in a research report on Monday, April 14th. Robert W. Baird dropped their target price on shares of Iovance Biotherapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a research report on Friday, February 28th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $32.00 price target on shares of Iovance Biotherapeutics in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $18.22.

Iovance Biotherapeutics Price Performance

Shares of NASDAQ:IOVA traded up $0.15 during midday trading on Friday, hitting $3.51. 14,756,313 shares of the company's stock were exchanged, compared to its average volume of 7,579,931. Iovance Biotherapeutics, Inc. has a 12 month low of $2.70 and a 12 month high of $14.23. The company has a market cap of $1.15 billion, a PE ratio of -2.36 and a beta of 1.05. The stock has a 50 day moving average price of $3.73 and a 200-day moving average price of $6.58.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last posted its earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.26). The company had revenue of $73.69 million for the quarter, compared to analyst estimates of $72.17 million. Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. On average, analysts anticipate that Iovance Biotherapeutics, Inc. will post -1.24 EPS for the current fiscal year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.